• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. A Study on the Body of Evidence for Harm in Evidence Based Medicine: A Call for Establishing Evidenc

A Study on the Body of Evidence for Harm in Evidence Based Medicine: A Call for Establishing Evidenc

来源 :2015第三届世界健康大会、首届国际失智症大会、第三届国际老年病学大会、第四届国际糖尿病学大会暨第五届国际内分泌与代谢大 | 被引量 : 0次 | 上传用户：jiangxiuli2010
【摘 要】
：
Harm (or safety) is an important part as well as effectiveness for an intervention in clinical practice, which is like two sides of a coin.However, no evidence ranking or grading systems are based on
【作 者】
：
Xing Liao Yanming Xie 
【机 构】
：
Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences China
【出 处】
：
2015第三届世界健康大会、首届国际失智症大会、第三届国际老年病学大会、第四届国际糖尿病学大会暨第五届国际内分泌与代谢大
【发表日期】
：
2015年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　Harm (or safety) is an important part as well as effectiveness for an intervention in clinical practice, which is like two sides of a coin.However, no evidence ranking or grading systems are based on safety research reality in Evidence based medicine.Existing evidence ranking or grading systems are prone to evaluating effectiveness evidence not proper for harm evidence.
其他文献
Pharmacokinetic/Pharmacodynamic Modeling: Effect of Ibutilide on the QTcF Interval in Healthy Male S
Background: Ibutilide, a class Ⅲ antiarrhythmic agent, is primarily used for conversion of atrial flutter and fibrillation and is a good alternative to electrical cardioversion.However, ibutilide incr
会议
pharmacokineticibutilideEmax model
Selecting the target dose for phase Ⅱ clinical test of new drug using population approach of pre-cli
Introduction and purpose: Influenza viruses can show resistance to anti-viral drugs.This can result from over-use of these drugs and also due to the ability of influenza virus to mutate rapidly.For th
会议
Influenza virusphase Ⅱ clinical trialNONMEMsimulationWinNolin
Application of Physiologically Based Pharmacokinetic Modeling in Apatinib Clinical Pharmacokinetic S
Outlines · Introduction · In vitro ADME Properties · PBPK Modeling · Clinical PK of Apatinib in Healthy Volunteers · Prediction of Food Effect on Apatinib PK and DDIs using PBPK Model Introduction · A
会议
The effect of poor compliance on the pharmacokinetics of valproic acid in children with epilepsy usi
Objective: To investigate the effects of delayed and missed doses(poor compliance) on the pharmacokinetics of valproic acid(VPA) in epileptic children using Monte Carlo simulation.Methods: VPA time-co
会议
Predictions about probabilities of adverse events and appropriate dose of roflumilast for Chinese CO
Backgrounds: Roflumilast is an oral inhibitor of phosphodiesterase 4(PDE4), which is mainly metabolized by CYP3A4 and CYP1A2.The main metabolite of it is roflumilast N-oxide, which contributes to the
会议
Optimizing dosage regimens of piperacillin/tazobactam based on population pharmacokinetic and pharma
Background Piperacillin/tazobactam is an extended-spectrum β-lactamase inhibitor combination antibiotic and is commonly recommended as a first-line therapy for severe bacterial infections.As a time-de
会议
Effect of Target-Mediated Drug Disposition on CPRC3 Pharmacokinetics and Pharmacodynamics in Healthy
Background: The prevalence of diabetes mellitus (DM) dramatically increased over the past decades.Dipeptidyl peptidase Ⅳ (DPP-4) inhibitors are a relatively new group of anti-diabetic agents.CPRC3 is
会议
DPP-4 inhibitorCPRC3pharmacokineticstarget-mediated drug disposition model
Combining “Bottom-up” and “Top-down” methods to assess ethnic difference in clearance of bitopertin
Outline ·Background and Objectives · Methods ·Results ·Discussion ·Conclusions Background-Bitopertin ·Bitopertin is a glycine reuptake inhibitor that is postulated to improve NMDA receptor hypofunctio
会议
Development Strategies of Anti-PD-1 mAb for Tumor Therapeutics in China for Global Market
Lower-incidence tumor types are expected to account for ＞50％ of sales by 2020Product life cycle has shortened by almost fivefold from HER2 to now
会议
TransCelerate Overview
Currently, 19 of the Worlds Most Successful Biopharmaceutical Companies Comprise TransCelerate Membership TransCelerate is a Nonprofit Entity Created in 2012 to Drive Collaboration
会议